Spreading the word: Precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein

Neuropathology and Applied Neurobiology

Volumn 42, Issue 1, 2016, Pages 51-76

  Rey, N L ^a   George, S ^a   Brundin, P ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Alpha synuclein; Braak staging; Cell to cell transfer; Lewy bodies; Multiple system atrophy; Parkinson's disease; Pathology spreading; Phosphorylated alpha synuclein; Prion like; Propagation

Indexed keywords

ALPHA SYNUCLEIN; PRION PROTEIN;

ANIMAL MODEL; CELL INTERACTION; DIFFUSE LEWY BODY DISEASE; LEWY BODY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; SHY DRAGER SYNDROME; TRANSGENIC RAT; WILD TYPE RAT; ANIMAL; DISEASE COURSE; DISEASE MODEL; HUMAN; METABOLISM; PATHOLOGY;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; LEWY BODY DISEASE; MULTIPLE SYSTEM ATROPHY;

EID: 84959183273     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/nan.12299     Document Type: Review

References (206)

1. Li J-Y, Englund E, Holton JL, Soulet D, Hagell P, Lees AJ, Lashley T, Quinn NP, Rehncrona S, Björklund A, Widner H, Revesz T, Lindvall O, Brundin P. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 2008; 14: 501-3.
2. Brundin P, Li J-Y, Holton JL, Lindvall O, Revesz T. Research in motion: the enigma of Parkinson's disease pathology spread. Nat Rev Neurosci 2008; 9: 741-5.
3. Aguzzi A, Rajendran L. Perspective. Neuron 2009; 64: 783-90.
4. Frost B, Diamond MI. Prion-like mechanisms in neurodegenerative diseases. Nat Rev Neurosci 2009; 17: 357-368.
5. Angot E, Brundin P. Dissecting the potential molecular mechanisms underlying alpha-synuclein cell-to-cell transfer in Parkinson's disease. Parkinsonism Relat Disord 2009; 15: S143-S147.
6. Braak H, del Tredici K, Rüb U, de Vos RA, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
7. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110: 517-36.
8. Braak H, Ghebremedhin E, Rüb U, Bratzke H, del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-34.
9. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DMA, Hasegawa M. Prion-like spreading of pathological α-synuclein in brain. Brain 2013; 136: 1128-38.
10. Reyes JF, Rey NL, Bousset L, Melki R, Brundin P, Angot E. Alpha-synuclein transfers from neurons to oligodendrocytes. Glia 2013; 62: 387-98.
11. Kisos H, Pukaß K, Ben-Hur T, Richter-Landsberg C, Sharon R. Increased neuronal α-synuclein pathology associates with its accumulation in oligodendrocytes in mice modeling α-synucleinopathies. PLoS One 2012; 7: e46817.
12. Konno M, Hasegawa T, Baba T, Miura E, Sugeno N, Kikuchi A, Fiesel FC, Sasaki T, Aoki M, Itoyama Y, Takeda A. Suppression of dynamin GTPase decreases α-synuclein uptake by neuronal and oligodendroglial cells: a potent therapeutic target for synucleinopathy. Mol Neurodegener 2012; 7: 38.
13. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VMY, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M, Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-72.
14. Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 2009; 1792: 730-40.
15. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011; 122: 187-204.
16. Gai WP, Power JH, Blumbergs PC, Culvenor JG, Jensen PH. Alpha-synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J Neurochem 1999; 73: 2093-100.
17. Ubhi K, Low P, Masliah E. Multiple system atrophy: a clinical and neuropathological perspective. Trends Neurosci 2011; 34: 581-90.
18. Jo E, McLaurin J, Yip CM, St George-Hyslop P, Fraser PE. Alpha-synuclein membrane interactions and lipid specificity. J Biol Chem 2000; 275: 34328-34.
19. El-Agnaf OMA, Irvine GB. Review: formation and Properties of Amyloid-like Fibrils Derived from α-Synuclein and Related Proteins. J Struct Biol 2000; 130: 300-9.
20. Kumar S, Sarkar A, Sundar D. Controlling aggregation propensity in A53T mutant of alpha-synuclein causing Parkinson's disease. Biochem Biophys Res Commun 2009; 387: 305-9.
21. Nielsen SB, Macchi F, Raccosta S, Langkilde AE, Giehm L, Kyrsting A, Svane ASP, Manno M, Christiansen G, Nielsen NC, Oddershede L, Vestergaard B, Otzen DE. Wildtype and A30P mutant alpha-synuclein form different fibril structures. PLoS One 2013; 8: e67713.
22. Costanzo M, Zurzolo C. The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration. Biochem J 2013; 452: 1-17.
23. Serpell LC, Berriman J, Jakes R, Goedert M, Crowther RA. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci USA 2000; 97: 4897-902.
24. Uversky VN, Eliezer D. Biophysics of Parkinson's Disease: structure and Aggregation of alpha-synuclein. Curr Protein Pept Sci 2009; 10: 483-99.
25. Rodriguez JA, Ivanova MI, Sawaya MR, Cascio D, Reyes FE, Shi D, Sangwan S, Guenther EL, Johnson LM, Zhang M, Jiang L, Arbing MA, Nannenga BL, Hattne J, Whitelegge J, Brewster AS, Messerschmidt M, Boutet S, Sauter NK, Gonen T, Eisenberg DS. Structure of the toxic core of α-synuclein from invisible crystals. Nature 2015; 525: 486-90.
26. Lewis KA, Yaeger A, DeMartino GN, Thomas PJ. Accelerated formation of α-synuclein oligomers by concerted action of the 20S proteasome and familial Parkinson mutations. J Bioenerg Biomembr 2010; 42: 85-95.
27. Goedert M. Alzheimer's and Parkinson's diseases: the prion concept in relation to assembled Aβ, tau, and α synuclein. Science 2015; 349: 1255555.
28. Emadi S, Kasturirangan S, Wang MS, Schulz P, Sierks MR. Detecting morphologically distinct oligomeric forms of alpha-synuclein. J Biol Chem 2009; 284: 11048-58.
29. Lashuel HA, Overk CR, Oueslati A, Masliah E. The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci 2012; 14: 38-48.
30. Caughey B, Lansbury PT. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu Rev Neurosci 2003; 26: 267-98.
31. Spillantini MG, Schmidt ML, Lee V, Trojanowski JQ. α-Synuclein in Lewy bodies. Nature 1997; 388: 839-40.
32. Braak H, Bohl JRR, Müller CM, Rüb U, de Vos RA, del Tredici K. Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson's disease reconsidered. Mov Disord 2006; 21: 2042-51.
33. Langston JW. The parkinson's complex: Parkinsonism is just the tip of the iceberg. Ann Neurol 2006; 59: 591-6.
34. Hawkes CH, del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord 2010; 16: 79-84.
35. Jellinger KA. Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm 2015; 122: 1429-40.
36. Pahwa R, Lyons KE. Handbook of Parkinson's Disease. Kindle edn. Boca Raton, Florida: CRC Press, 2013.
37. Braak H, del Tredici K. Poor and protracted myelination as a contributory factor to neurodegenerative disorders. Neurobiol Aging 2004; 25: 19-23.
38. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007; 33: 599-614.
39. Hawkes CH, del Tredici K, Braak H. Parkinson's disease: the dual hit theory revisited. Ann N Y Acad Sci 2009; 1170: 615-22.
40. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RKB. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease: a critical analysis of α-synuclein staging. Neuropathol Appl Neurobiol 2008; 34: 284-95.
41. Burke RE, Dauer WT, Vonsattel JPG. A critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2008; 64: 485-91.
42. Dickson DW, Uchikado H, Fujishiro H, Tsuboi Y. Evidence in favor of Braak staging of Parkinson's disease. Mov Disord 2010; 25: S78-S82.
43. Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance. Acta Neuropathol 2008; 115: 399-407.
44. Wakabayashi K, Tanji K, Odagiri S, Miki Y, Mori F, Takahashi H. The Lewy Body in Parkinson's Disease and Related Neurodegenerative Disorders. Mol Neurobiol 2012; 47: 495-508.
45. Jellinger KA. Neuropathology of sporadic Parkinson's disease: evaluation and changes of concepts. Mov Disord 2011; 27: 8-30.
46. Jellinger KA. Critical evaluation of the Braak staging scheme for Parkinson's disease. Ann Neurol 2009; 67: 550.
47. Jellinger KA. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution-a pilot study. Acta Neuropathol 2003; 106: 191-201.
48. Dickson DW, Fujishiro H, DelleDonne A, Menke J, Ahmed Z, Klos KJ, Josephs KA, Frigerio R, Burnett M, Parisi JE, Ahlskog JE. Evidence that incidential Lewy body disease is pre-symptomatic parkinson's disease. Acta Neuropathol 2008; 115: 437-44.
49. Frigerio R, Fujishiro H, Ahn T-B, Josephs KA, Maraganore DM, DelleDonne A, Parisi JE, Klos KJ, Boeve BF, Dickson DW, Ahlskog JE. Incidental Lewy body disease: do some cases represent a preclinical stage of dementia with Lewy bodies? Neurobiol Aging 2011; 32: 857-63.
50. Halliday G, McCann H, Shepherd C. Evaluation of the Braak hypothesis: how far can it explain the pathogenesis of Parkinson's disease? Expert Rev Neurother 2012; 12: 673-86.
51. Saito Y, Kawashima A, Ruberu NN, Fujiwara H, Koyama S, Sawabe M, Arai T, Nagura H, Yamanouchi H, Hasegawa M, Iwatsubo T, Murayama S. Accumulation of phosphorylated alpha-synuclein in aging human brain. J Neuropathol Exp Neurol 2003; 62: 1-11.
52. Eberling JL, Dave KD, Frasier MA. α-synuclein imaging: a critical need for Parkinson's disease research. J Parkinsons Dis 2013; 3: 565-7.
53. Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, Sørensen HT. Vagotomy and subsequent risk of Parkinson's disease. Ann Neurol 2015; 78: 522-9.
54. Mendes A, Gonçalves A, Vila-Chã N, Moreira I, Fernandes J, Damásio J, Teixeira-Pinto A, Taipa R, Lima AB, Cavaco S. Appendectomy may delay Parkinson's disease Onset. Mov Disord 2015; 30: 1404-7.
55. Baba M, Nakajo S, Tu P-H, Tomita T, Nakaya K, Lee VMY, Trojanowski JQ, Iwatsubo T. Aggregation of alpha-synuclein in Lewy Bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol 1998; 152: 879-84.
56. Culvenor JG, McLean CA, Cutt S, Campbell BCV, Maher F, Jäkälä P, Hartmann T, Beyreuther K, Masters CL, Li Q-X. Non-Aβ component of Alzheimer's Disease Amyloid (NAC) revisited. Am J Pathol 1999; 155: 1-9.
57. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aarsland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, Trojanowski JQ, Wszolek ZK. DLB and PDD boundary issues; diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-9.
58. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree-a new disease? Clin Neuropathol 1984; 3: 185-92.
59. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, P QN, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, De Vos RA, Wilcock GK, Jellinger KA, Perry RH. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-24.
60. Alafuzoff I, Parkkinen L. Parkinsonism and Related Disorders. Parkinsonism Relat Disord 2013; 20: S57-S61.
61. Leverenz JB, Hamilton R, Tsuang DW, Schantz A, Vavrek D, Larson EB, Kukull WA, Lopez O, Galasko D, Masliah E, Kaye J, Woltjer R, Clark C, Trojanowski JQ, Montine TJ. Empiric refinement of the pathologic assessment of Lewy-related pathology in the dementia patient. Brain Pathol 2008; 18: 220-4.
62. Alafuzoff I, Ince PG, Arzberger T, Al-Sarraj S, Bell J, Bodi I, Bogdanovic N, Bugiani O, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Ironside JW, Kavantzas N, King A, Korkolopoulou P, Kovacs GG, Meyronet D, Monoranu C, Parchi P, Parkkinen L, Patsouris E, Roggendorf W, Rozemuller A, Stadelmann-Nessler C, Streichenberger N, Thal DR, Kretzschmar H. Staging/typing of Lewy body related α-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathol 2009; 117: 635-52.
63. Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, Sasse J, Boyer S, Shirohi S, Brooks R, Eschbacher J, White CL, Akiyama H, Caviness J, Shill HA, Connor DJ, Sabbagh MN, Walker DG. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 2009; 117: 613-34.
64. Sengoku R, Saito Y, Ikemura M, Hatsuta H, Sakiyama Y, Kanemaru K, Arai T, Sawabe M, Tanaka N, Mochizuki H, Inoue K, Murayama S. Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J Neuropathol Exp Neurol 2008; 67: 1072-83.
65. Funabe S, Takao M, Saito Y, Hatsuta H, Sugiyama M, Ito S, Kanemaru K, Sawabe M, Arai T, Mochizuki H, Hattori N, Murayama S. Neuropathologic analysis of Lewy-related α-synucleinopathy in olfactory mucosa. Neuropathology 2012; 33: 47-58.
66. Ito S, Takao M, Hatsuta H, Kanemaru K, Arai T, Saito Y, Fukayama M, Murayama S. Alpha-synuclein immunohistochemistry of gastrointestinal and biliary surgical specimens for diagnosis of Lewy body disease. Int J Clin Exp Pathol 2014; 7: 1714-23.
67. Ikemura M, Saito Y, Sengoku R, Sakiyama Y, Hatsuta H, Kanemaru K, Sawabe M, Arai T, Ito G, Iwatsubo T, Fukayama M, Murayama S. Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 2008; 67: 945-53.
68. Nishie M, Mori F, Fujiwara H, Hasegawa M, Yoshimoto M, Iwatsubo T, Takahashi H, Wakabayashi K. Accumulation of phosphorylated α-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol 2004; 107: 292-8.
69. Spillantini MG, Goedert M, Hasegawa M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 1998; 95: 6469-73.
70. Wenning GK, Jellinger KA. The role of alpha-synuclein in the pathogenesis of multiple system atrophy. Acta Neuropathol 2005; 109: 129-40.
71. Lyoo CH, Jeong Y, Ryu YH, Lee SY, Song TJ, Lee JH, Rinne JO, Lee MS. Effects of disease duration on the clinical features and brain glucose metabolism in patients with mixed type multiple system atrophy. Brain 2008; 131: 438-46.
72. Markopoulou K, Dickson DW, McComb RD, Wszolek ZK, Katechalidou L, Avery L, Stansbury MS, Chase BA. Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinson's disease. Acta Neuropathol 2008; 116: 25-35.
73. Deng H, Yuan L. Genetic variants and animal models in SNCA and Parkinson disease. Ageing Res Rev 2014; 15: 161-76.
74. Gwinn-Hardy K, Mehta ND, Farrer M, Maraganore D, Muenter M, Yen SH, Hardy J, Dickson DW. Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p. Acta Neuropathol 2000; 99: 663-72.
75. Kiely AP, Asi YT, Kara E, Limousin P, Ling H, Lewis P, Proukakis C, Quinn N, Lees AJ, Hardy J, Revesz T, Houlden H, Holton JL. α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy? Acta Neuropathol 2013; 125: 753-69.
76. Pasanen P, Myllykangas L, Siitonen M, Raunio A, Kaakkola S, Lyytinen J, Tienari PJ, Pöyhönen M, Paetau A. A novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology. Neurobiol Aging 2014; 35: 2180.e1-5.
77. Xu W, Tan L, Yu J-T. The link between the SNCA gene and parkinsonism. Neurobiol Aging 2015; 36: 1505-18.
78. Miller DW, Johnson JM, Solano SM, Hollingsworth ZR, Standaert DG, Young AB. Absence of α-synuclein mRNA expression in normal and multiple system atrophy oligodendroglia. J Neural Transm 2005; 112: 1613-24.
79. Asi YT, Simpson JE, Heath PR, Wharton SB, Lees AJ, Revesz T, Houlden H, Holton JL. Alpha-synuclein mRNA expression in oligodendrocytes in MSA. Glia 2014; 62: 964-70.
80. Djelloul M, Holmqvist S, Boza-Serrano A, Azevedo C, Yeung MS, Goldwurm S, Frisén J, Deierborg T, Roybon L. Alpha-synuclein expression in the oligodendrocyte lineage: an in vitro and in vivo study using rodent and human models. Stem Cell Reports 2015; 5: 174-84.
81. Kurowska Z, Englund E, Widner H, Lindvall O, Li J-Y, Brundin P. Signs of degeneration in 12-22 years old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. J Parkinsons Dis 2011; 1: 83-92.
82. Li J-Y, Englund E, Widner H, Rehncrona S, Björklund A, Lindvall O, Brundin P. Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord 2010; 25: 1091-6.
83. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008; 14: 504-6.
84. Desplats P, Lee H-J, Bae E-J, Patrick C, Rockenstein E, Crews L, Spencer B, Masliah E, Lee S-J. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc Natl Acad Sci U S A 2009; 106: 13010-5.
85. Kordower JH, Dodiya HB, Kordower AM, Terpstra B, Paumier K, Madhavan L, Sortwell C, Steece-Collier K, Collier TJ. Transfer of host-derived alpha-synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis 2011; 43: 552-7.
86. Angot E, Steiner JA, Lema Tomé CM, Ekström P, Mattsson B, Björklund A, Björklund A, Brundin P. Alpha-Synuclein Cell-to-Cell Transfer and Seeding in Grafted Dopaminergic Neurons In Vivo. PLoS One 2012; 7: e39465.
87. Hansen C, Angot E, Bergström A-L, Steiner JA, Pieri L, Paul G, Outeiro TF, Melki R, Kallunki P, Fog K, Li J-Y, Brundin P. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest 2011; 121: 715-25.
88. Jucker M, Walker LC. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 2013; 501: 45-51.
89. Dujardin S, Colin M, Buee L. Invited review: Animal models of tauopathies and their implications for research/translation into the clinic. Neuropathol Appl Neurobiol 2015; 41: 59-80.
90. Tuite MF, Koloteva-Levin N. Propagating prions in fungi and mammals. Mol Cell 2004; 14: 541-52.
91. Rey NL, Petit GH, Bousset L, Melki R, Brundin P. Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice. Acta Neuropathol 2013; 126: 555-73.
92. Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björklund T, Wang Z-Y, Roybon L, Melki R, Li J-Y. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 2014; 128: 805-20.
93. Dunning CJR, Reyes JF, Steiner JA, Brundin P. Can Parkinson's disease pathology be propagated from one neuron to another? Prog Neurobiol 2012; 97: 205-19.
94. Freundt EC, Maynard N, Clancy EK, Roy S, Bousset L, Sourigues Y, Covert M, Melki R, Kirkegaard K, Brahic M. Neuron-to-neuron transmission of α-synuclein fibrils through axonal transport. Ann Neurol 2012; 72: 517-24.
95. Recasens A, Dehay B. Alpha-synuclein spreading in Parkinson's disease. Front Neuroanat 2014; 8: 159.
96. Ulusoy A, Rusconi R, Pérez-Revuelta BI, Musgrove RE, Helwig M, Winzen-Reichert B, et al. Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med 2013; 5: 1119-27.
97. Ulusoy A, Musgrove RE, Rusconi R, Klinkenberg M, Helwig M, Schneider A, Di Monte DA. Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathol Commun 2015; 3: 13.
98. Mougenot A-L, Nicot S, Bencsik A, Morignat E, Verchère J, Lakhdar L, Legastelois S, Baron T. Prion-like acceleration of a synucleinopathy in a transgenic mouse model. Neurobiol Aging 2012; 33: 2225-8.
99. Luk KC, Kehm VM, Zhang B, O'Brien P, Trojanowski JQ, Lee VMY. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice. J Exp Med 2012; 209: 975-86.
100. Sacino AN, Brooks M, Thomas MA, McKinney AB, Lee S, Regenhardt RW, McGarvey NH, Ayers JI, Notterpek L, Borchelt DR, Golde TE, Giasson BI. Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci 2014; 111: 10732-7.
101. Sacino AN, Brooks M, McGarvey NH, McKinney AB, Thomas MA, Levites Y, Ran Y, Golde TE, Giasson BI. Induction of CNS α-synuclein pathology by fibrillar and non-amyloidogenic recombinant α-synuclein. Acta Neuropathol Commun 2013; 1: 38.
102. Sacino AN, Brooks M, Thomas MA, McKinney AB, McGarvey NH, Rutherford NJ, Ceballos-Diaz C, Robertson J, Golde TE, Giasson BI. Amyloidogenic a-synuclein seeds do not invariably induce rapid, widespread pathology in mice. Acta Neuropathol 2014; 127: 645-65.
103. Bernis ME, Babila JT, Breid S, Wüsten KA, Wüllner U, Tamgüney G. Prion-like propagation of humanbrain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol Commun 2015; 3: 75.
104. Jones DR, Delenclos M, Baine AT, DeTure M, Murray ME, Dickson DW, McLean PJ. Transmission of Soluble and Insoluble α-Synuclein to Mice. J Neuropathol Exp Neurol 2015; 74: 1158-69.
105. Dehay B, Bézard E, Brundin P, Kordower JH. Alpha-synuclein propagation: new insights from animal models. Mov Disord 2015; doi: 10.1002/mds.26370.
106. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, Lee VMY. Pathological α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 2012; 338: 949-53.
107. Masuda-Suzukake M, Nonaka T, Hosokawa M, Kubo M, Shimozawa A, Akiyama H, Hasegawa M. Pathological alpha-synuclein propagates through neural networks. Acta Neuropathol Commun 2014; 2: 88.
108. Volpicelli-Daley LA, Luk KC, Lee VMY. Addition of exogenous α-synuclein preformed fibrils to primary neuronal cultures to seed recruitment of endogenous α-synuclein to Lewy body and Lewy neurite-like aggregates. Nat Protoc 2014; 9: 2135-46.
109. Peelaerts W, Bousset L, Van der Perren A, Moskalyuk A, Pulizzi R, Giugliano M, Van den Haute C, Melki R, Baekelandt V. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 2015; 522: 340-4.
110. Recasens A, Dehay B, Bové J, Carballo-Carbajal I, Dovero S, Pérez-Villalba A, Fernagut P-O, Blesa J, Parent A, Perier C, Fariñas I, Obeso JA, Bézard E, Vila M. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys. Ann Neurol 2014; 75: 351-62.
111. Goedert M. Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci 2001; 2: 492-501.
112. Norris EH, Giasson BI, Lee VM. Alpha-synuclein: normal function and role in neurodegenerative diseases. Curr Top Dev Biol 2004; 60: 17-54.
113. Lippa CF, Fujiwara H, Mann DM, Giasson B, Baba M, Schmidt ML, Nee LE, O'Connell B, Pollen DA, St George-Hyslop P, Ghetti B, Nochlin D, Bird TD, Cairns NJ, Lee VM, Iwatsubo T, Trojanowski JQ. Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am J Pathol 1998; 153: 1365-70.
114. Ishikawa A, Piao Y-S, Kuwano R, Onodera O, Ohtake H, Suzuki M, Nishizawa M, Takahashi H. A mutant PSEN1 causes dementia with Lewy bodies and variant Alzheimer's disease. Ann Neurol 2005; 57: 429-34.
115. Moussaud S, Jones DR, Moussaud-Lamodière EL, Delenclos M, Ross OA, McLean PJ. Alpha-synuclein and tau: teammates in neurodegeneration? Mol Neurodegener 2014; 9: 43.
116. Sengupta U, Guerreiro MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, Paulucci-Holthauzen AA, Krishnamurthy S, Farhed M, Jackson GR, Kayed R. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychol 2015; 78: 672-83.
117. Westermark P, Westermark GT. Seeding and Cross-seeding in Amyloid Diseases. In Proteopathic Seeds and Neurodegenerative Diseases. Ed M Jucker . 2013: Springer (IPSEN book series), Berlin Heidelberg, Germany; 47-60.
118. Ono K, Takahashi R, Ikeda T, Mizuguchi M, Hamaguchi T, Yamada M. Exogenous amyloidogenic proteins function as seeds in amyloid β-protein aggregation. Biochim Biophys Acta 2014; 1842: 646-53.
119. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J, Soto C. Molecular Cross Talk between Misfolded Proteins in Animal Models of Alzheimer's and Prion Diseases. J Neurosci 2010; 30: 4528-35.
120. Morales R, Moreno-Gonzalez I, Soto C. Cross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseases. PLoS Pathog 2013; 9: e1003537.
121. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, Riddle DM, Kwong LK, Xu Y, Trojanowski JQ, Lee VMY. Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons. Cell 2013; 154: 103-17.
122. Pan-Montojo F, Anichtchik O, Dening Y, Knels L, Pursche S, Jung R, Jackson S, Gille G, Spillantini MG, Reichmann H, Funk RHW. Progression of Parkinson's Disease Pathology Is Reproduced by Intragastric Administration of Rotenone in Mice. PLoS One 2010; 5: e8762.
123. Pan-Montojo F, Schwarz M, Winkler C, Arnhold M, O'Sullivan GA, Pal A, Said J, Marsico G, Verbavatz J-M, Rodrigo-Angulo M, Gille G, Funk RHW, Reichmann H. Environmental toxins trigger PD-like progression via increased alpha-synuclein release from enteric neurons in mice. Sci Rep 2012; 2: 898.
124. Cremades N, Cohen SIA, Deas E, Abramov AY, Chen AY, Orte A, Sandal M, Clarke RW, Dunne P, Aprile FA, Bertoncini CW, Wood NW, Knowles TPJ, Dobson CM, Klenerman D. Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein. Cell 2012; 149: 1048-59.
125. van Raaij ME, van Gestel J, Segers-Nolten IMJ, de Leeuw SW, Subramaniam V. Concentration dependence of α-Synuclein fibril length assessed by quantitative atomic force microscopy and statistical-mechanical theory. Biophys J 2008; 95: 4871-8.
126. Segers-Nolten IMJ, Wilhelmus MMM, Veldhuis G, van Rooijen BD, Drukarch B, Subramaniam V. Tissue transglutaminase modulates α-synuclein oligomerization. Protein Sci 2008; 17: 1395-402.
127. Shtilerman MD, Ding TT, Lansbury PT. Molecular crowding accelerates fibrillization of α-synuclein: Could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry 2002; 41: 3855-60.
128. Wood SJ, Wypych J, Steavenson S, Louis J-C, Citron M, Biere AL. α-Synuclein fibrillogenesis is nucleation-dependent. J Biol Chem 1999; 274: 19509-12.
129. Baldwin AJ, Knowles TPJ, Tartaglia GG, Fitzpatrick AW, Devlin GL, Shammas SL, Waudby CA, Mossuto MF, Meehan S, Gras SL, Christodoulou J, Anthony-Cahill SJ, Barker PD, Vendruscolo M, Dobson CM. Metastability of native proteins and the phenomenon of amyloid formation. J Am Chem Soc 2011; 133: 14160-3.
130. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT Jr. α-Synuclein, Especially the Parkinson's Disease-associated Mutants, Forms Pore-like Annular and Tubular Protofibrils. J Mol Biol 2002; 322: 1089-102.
131. Smith DP, Tew DJ, Hill AF, Bottomley SP, Masters CL, Barnham KJ, Cappai R. Formation of a high affinity lipid-binding intermediate during the early aggregation phase of α-synuclein. Biochemistry 2008; 47: 1425-34.
132. Rabe M, Soragni A, Reynolds NP, Verdes D, Liverani E, Riek R, Seeger S. On-surface aggregation of α-synuclein at nanomolar concentrations results in two distinct growth mechanisms. ACS Chem Neurosci 2013; 4: 408-17.
133. Buell AK, Galvagnion C, Gaspar R, Sparr E, Vendruscolo M, Knowles TPJ, Linse S, Dobson CM. Solution conditions determine the relative importance of nucleation and growth processes in -synuclein aggregation. Proc Natl Acad Sci 2014; 111: 7671-6.
134. Fonseca T, Villar-Piqué A, Outeiro T. The Interplay between Alpha-Synuclein Clearance and Spreading. Biomolecules 2015; 5: 435-71.
135. Aguzzi A, Calella AM. Prions: protein aggregation and infectious diseases. Physiol Rev 2009; 89: 1105-52.
136. Busquets MA, Espargaró A, Estelrich J, Sabate R. Could α-Synuclein Amyloid-Like Aggregates Trigger a Prionic Neuronal Invasion? Biomed Res Int 2015; 2015: 1-7.
137. Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol 2005; 75: 109-24.
138. Xu S, Chan P. Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease. Biomolecules 2015; 5: 1122-42.
139. Obi K, Akiyama H, Kondo H, Shimomura Y, Hasegawa M, Iwatsubo T, Mizuno Y, Mochizuki H. Relationship of phosphorylated α-synuclein and tau accumulation to Aβ deposition in the cerebral cortex of dementia with Lewy bodies. Exp Neurol 2008; 210: 409-20.
140. Beach TG, adler CH, Sue LI, Vedders L, Lue L, White CLIII, Akiyama H, Caviness JN, Shill HA, Sabbagh MN, Walker DG, Arizona Parkinson's Disease Consortium. Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol 2010; 119: 689-702.
141. Walker DG, Lue L-F, adler CH, Shill HA, Caviness JN, Sabbagh MN, Akiyama H, Serrano GE, Sue LI, Beach TG, Consortium APD. Changes in properties of serine 129 phosphorylated α-synuclein with progression of Lewy-type histopathology in human brains. Exp Neurol 2013; 240: 190-204.
142. Watts JC, Giles K, Oehler A, Middleton L, Dexter DT, Gentleman SM, DeArmond SJ, Prusiner SB. Transmission of multiple system atrophy prions to transgenic mice. Proc Natl Acad Sci 2013; 110: 19555-60.
143. Osterberg VR, Spinelli KJ, Weston LJ, Luk KC, Woltjer RL, Unni VK. Progressive aggregation of alpha-synuclein and selective degeneration of Lewy inclusion-bearing neurons in a mouse model of Parkinsonism. Cell Rep 2015; 10: 1252-60.
144. Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ, Steece-Collier K, Kemp CJ, Celano S, Schulz E, Sandoval IM, Fleming S, Dirr E, Polinski NK, Trojanowski JQ, Lee VM, Sortwell CE. Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration. Neurobiol Dis 2015; 82: 185-99.
145. Oueslati A, Fournier M, Lashuel HA. Role of post-translational modifications in modulating the structure, function and toxicity of α-synuclein. In Progress in Brain Research. Ed A Björklund and MA Cenci; Academic Press, Cambridge, Massachusetts, USA, 2010; 115-45.
146. Ellis CE, Schwartzberg PL, Grider TL, Fink DW, Nussbaum RL. Synuclein Is Phosphorylated by Members of the Src Family of Protein-tyrosine Kinases. J Biol Chem 2001; 276: 3879-84.
147. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002; 4: 160-4.
148. Kellie JF, Higgs RE, Ryder JW, Major A, Beach TG, Adler CH, Merchant K, Knierman M. Quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry. Sci Rep 2014; 4: 5797.
149. Muntané G, Ferrer I, Martinez-Vicente M. α-synuclein phosphorylation and truncation are normal events in the adult human brain. Neuroscience 2012; 200: 106-19.
150. Lue L-F, Walker DG, adler CH, Shill H, Tran H, Akiyama H, Sue LI, Caviness J, Sabbagh MN, Beach TG. Biochemical Increase in Phosphorylated Alpha-Synuclein Precedes Histopathology of Lewy-Type Synucleinopathies. Brain Pathol 2012; 22: 745-56.
151. Surgucheva I, Newell KL, Burns J, Surguchov A. New α- and γ-synuclein immunopathological lesions in human brain. Acta Neuropathol Commun 2014; 2: 132.
152. Homma T, Mochizuki Y, Mizutani T. Phosphorylated α-synuclein immunoreactivity in the posterior pituitary lobe. Neuropathology 2011; 32: 385-9.
153. Saito Y, Kawai M, Inoue K, Sasaki R, Arai H, Nanba E, Kuzuhara S, Ihara Y, Kanazawa I, Murayama S. Widespread expression of α-synuclein and τ immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course. J Neurol Sci 2000; 177: 48-59.
154. Nakamura K, Mori F, Kon T, Tanji K, Miki Y, Tomiyama M, Kurotaki H, Toyoshima Y, Kakita A, Takahashi H, Yamada M, Wakabayashi K. Filamentous aggregations of phosphorylated α-synuclein in Schwann cells (Schwann cell cytoplasmic inclusions) in multiple system atrophy. Acta Neuropathol Commun 2015; 3: 29.
155. Beach TG, Carew J, Serrano G, Adler CH, Shill HA, Sue LI, Sabbagh MN, Akiyama H, Cuenca N, Consortium TAPD. Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson's disease subjects. Neurosci Lett 2014; 571: 34-8.
156. Zange L, Noack C, Hahn K, Stenzel W, Lipp A. Phosphorylated α-synuclein in skin nerve fibres differentiates Parkinson's disease from multiple system atrophy. Brain 2015; 138: 2310-21.
157. Waxman EA, Duda JE, Giasson BI. Characterization of antibodies that selectively detect α-synuclein in pathological inclusions. Acta Neuropathol 2008; 116: 37-46.
158. Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, Kahle PJ, Hirling H, Lashuel HA. Phosphorylation of Synucleins by Members of the Polo-like Kinase Family. J Biol Chem 2010; 285: 2807-22.
159. Anderson JP, Walker DE, Goldstein JM, de Laat R, Banducci K, Caccavello RJ, Barbour R, Huang J, Kling K, Lee M, Diep L, Keim PS, Shen X, Chataway T, Schlossmacher MG, Seubert P, Schenk D, Sinha S, Gai W-P, Chilcote TJ. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J Biol Chem 2006; 281: 29739-52.
160. Wakamatsu M, Ishii A, Ukai Y, Sakagami J, Iwata S, Ono M, Matsumoto K, Nakamura A, Tada N, Kobayashi K, Iwatsubo T, Yoshimoto M. Accumulation of phosphorylated α-synuclein in dopaminergic neurons of transgenic mice that express human α-synuclein. J Neurosci Res 2007; 85: 1819-25.
161. Schell H, Hasegawa T, Neumann M, Kahle PJ. Nuclear and neuritic distribution of serine-129 phosphorylated α-synuclein in transgenic mice. Neuroscience 2009; 160: 796-804.
162. Bencsik A, Muselli L, Leboidre M, Lakhdar L, Baron T. Early and persistent expression of phosphorylated α-synuclein in the enteric nervous system of A53T mutant human α-synuclein transgenic mice. J Neuropathol Exp Neurol 2014; 73: 1144-51.
163. Sato H, Arawaka S, Hara S, Fukushima S, Koga K, Koyama S, Kato T. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci 2011; 31: 16884-94.
164. Watts JC, Condello C, Stohr J, Oehler A, Lee J, DeArmond SJ, Lannfelt L, Ingelsson M, Giles K, Prusiner SB. Serial propagation of distinct strains of Aβ prions from Alzheimer's disease patients. Proc Natl Acad Sci 2014; 111: 10323-8.
165. Duda JE, Giasson BI, Chen Q, Gur TL, Hurtig HI, Stern MB, Gollomp SM, Ischiropoulos H, Lee VM, Trojanowski JQ. Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol 2000; 157: 1439-45.
166. Tenreiro S, Eckerman K, Outeiro TF. Protein phosphorylation in neurodegeneration: friend or foe? frontiers in molecular neuroscience 2014; 7: 42.
167. Xu Y, Deng Y, Qing H. The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease. J Neurochem 2015; 135: 4-18.
168. Machiya Y, Hara S, Arawaka S, Fukushima S, Sato H, Sakamoto M, Koyama S, Kato T. Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome pathway in a ubiquitin-independent manner. J Biol Chem 2010; 285: 40732-44.
169. Zhou J, Broe M, Huang Y, Anderson JP, Gai W-P, Milward EA, Porritt M, Howells D, Hughes AJ, Wang X, Halliday GM. Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson's disease. Acta Neuropathol 2011; 121: 695-704.
170. Foulds P, Mann DM, Allsop D. Phosphorylated α-synuclein as a potential biomarker for Parkinson's disease and related disorders. Expert Review of Molecular Diagnostics 2012; 12: 115-7.
171. Foulds PG, Mitchell JD, Parker A, Turner R, Green G, Diggle P, Hasegawa M, Taylor M, Mann D, Allsop D. Phosphorylated α-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J 2011; 25: 4127-37.
172. Wang Y, Shi M, Chung KA, Zabetian CP, Leverenz JB, Berg D, Srulijes K, Trojanowski JQ, Lee VMY, Siderowf AD, Hurtig H, Litvan I, Schiess MC, Peskind ER, Masuda M, Hasegawa M, Lin X, Pan C, Galasko D, Goldstein DS, Jensen PH, Yang H, Cain KC, Zhang J. Phosphorylated α-synuclein in Parkinson's disease. Sci Transl Med 2012; 4: 121ra20.
173. Stewart T. Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol Commun 2015; 3: 7.
174. McCormack AL, Mak SK, Di Monte DA. Increased alpha-synuclein phosphorylation and nitration in the aging primate substantia nigra. Cell Death Dis 2012; 3: e315-9.
175. Canron M-H, Perret M, Vital A, Bézard E, Dehay B. Age-dependent α-synuclein aggregation in the Microcebus murinus lemur primate. Sci Rep 2012; 2: 910.
176. Fukui Y, Yamashita T, Kurata T, Sato K, Lukic V, Hishikawa N, Deguchi K, Abe K. Protective effect of telmisartan against progressive oxidative brain damage and synuclein phosphorylation in stroke-resistant spontaneously hypertensive rats. J Stroke Cerebrovasc Dis 2014; 23: 1545-53.
177. Chau K-Y, Ching HL, Schapira AHV, Cooper JM. Relationship between alpha-synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis. J Neurochem 2009; 110: 1005-13.
178. Hirai Y, Fujita SC, Iwatsubo T, Hasegawa M. Phosphorylated α-synuclein in normal mouse brain. FEBS Lett 2004; 572: 227-32.
179. Oueslati A, Schneider BL, Aebischer P, Lashuel HA. Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A 2013; 110: E3945-54.
180. Kragh CL, Lund LB, Febbraro F, Hansen HD, Gai W-P, El-Agnaf O, Richter-Landsberg C, Jensen PH. Alpha-synuclein aggregation and Ser-129 phosphorylation-dependent cell death in oligodendroglial cells. J Biol Chem 2009; 284: 10211-22.
181. Gonçalves S, Outeiro TF. Assessing the Subcellular Dynamics of Alpha-synuclein Using Photoactivation Microscopy. Mol Neurobiol 2013; 47: 1081-92.
182. Miake H, Mizusawa H, Iwatsubo T, Hasegawa M. Biochemical characterization of the core structure of alpha-synuclein filaments. J Biol Chem 2002; 277: 19213-9.
183. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Müller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, Haass C. Misfolded proteinase K-resistant hyperphosphorylated α-synuclein in aged transgenic mice with locomotor deterioration and in human α-synucleinopathies. J. Clin. Invest. 2002; 110: 1429-39.
184. Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain 2015; 138: 1642-57.
185. Dimant H, Kalia SK, Kalia LV, Zhu LN, Kibuuka L, Ebrahimi-Fakhari D, et al. Direct detection of alpha-synuclein oligomers in vivo. Acta Neuropathol Commun 2013; 1: 6.
186. Spinelli KJ, Taylor JK, Osterberg VR, Churchill MJ, Pollock E, Moore C, Meshul CK, Unni VK. Presynaptic Alpha-Synuclein Aggregation in a Mouse Model of Parkinson's Disease. J Neurosci 2014; 34: 2037-50.
187. Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Sisk A, Masliah E. Abnormal distribution of the non-Aβ component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment. Lab Invest 1998; 78: 1169-77.
188. Dale GE, Probst A, Luthert P, Martin J, Anderton BH, Leigh PN. Relationships between Lewy bodies and pale bodies in Parkinson's disease. Acta Neuropathol 1992; 83: 525-9.
189. Beach TG, White CL, Hamilton RL, Duda JE, Iwatsubo T, Dickson DW, Leverenz JB, Roncaroli F, Buttini M, Hladik CL, Sue LI, Noorigian JV, Adler CH. Evaluation of α-synuclein immunohistochemical methods used by invited experts. Acta Neuropathol 2008; 116: 277-88.
190. Beach TG, Tago H, Nagai T, Kimura H, McGeer PL. Perfusion-fixation of the human brain for immunohistochemistry: comparison with immersion-fixation. J Neurosci Methods 1987; 19: 183-92.
191. Swirski M, Miners JS, de Silva R, Lashley T, Ling H, Holton J, Revesz T, Love S. Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. Alzheimers Res Ther 2014; 6: 77.
192. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 2000; 290: 985-9.
193. Duda JE, Giasson BI, Mabon ME, Lee VMY, Trojanowski JQ. Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol 2002; 52: 205-10.
194. Lee FKM, Wong AKY, Lee YW, Wan OW. Edwin Chan HY, Chung KKK. The role of ubiquitin linkages on α-synuclein induced-toxicity in a Drosophila model of Parkinson's disease. J Neurochem 2009; 110: 208-19.
195. Sampathu DM, Giasson BI, Pawlyk AC, Trojanowski JQ, Lee VMY. Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am J Pathol 2003; 163: 91-100.
196. Gomez-Tortosa E, Newell K, Irizarri MC, Sanders JL, Hyman BT. Alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol 2000; 99: 352-7.
197. Kuusisto E, Parkkinen L, Alafuzoff I. Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. J Neuropathol Exp Neurol 2003; 62: 1241-53.
198. Watanabe Y, Tatebe H, Taguchi K, Endo Y, Tokuda T, Mizuno T, Nakagawa M, Tanaka M. p62/SQSTM1-Dependent Autophagy of Lewy Body-Like α-Synuclein Inclusions. PLoS One 2012; 7: e52868.
199. Braak H, Thal DR, del Tredici K. Nerve cells immunoreactive for p62 in select hypothalamic and brainstem nuclei of controls and Parkinson's disease cases. J Neural Transm 2010; 118: 809-19.
200. Paumier KL, Sukoff Rizzo SJ, Berger Z, Chen Y, Gonzales C, Kaftan E, Li L, Lotarski S, Monaghan M, Shen W, Stolyar P, Vasilyev D, Zaleska M, D Hirst W, Dunlop J. Behavioral Characterization of A53T Mice Reveals Early and Late Stage Deficits Related to Parkinson's Disease. PLoS One 2013; 8: e70274.
201. Kelly JW. Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 1996; 6: 11-7.
202. Bulic B, Pickhardt M, Mandelkow E-M, Mandelkow E. Tau protein and tau aggregation inhibitors. Neuropharmacology 2010; 59: 276-89.
203. Mollenhauer B, Trautmann E, Otte B, Ng J, Spreer A, Lange P, Sixel-Döring F, Hakimi M, VonSattel J-P, Nussbaum R, Trenkwalder C, Schlossmacher MG. α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system. J Neural Transm 2012; 119: 739-46.
204. El-Agnaf OMA, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, Allsop D. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006; 20: 419-25.
205. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SAS, Kasai T, Ishigami N, Tamaoka A, Nakagawa M, El-Agnaf OMA. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 2010; 75: 1766-72.
206. Vaikath NN, Majbour NK, Paleologou KE, Ardah MT, van Dam E, van de Berg WDJ, Forrest SL, Parkkinen L, Gai W-P, Hattori N, Takanashi M, Lee S-J, Mann DMA, Imai Y, Halliday GM, Li J-Y, El-Agnaf OMA. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology. Neurobiol Dis 2015; 79: 81-99.